Avita Medical Ltd.宣布,其关键临床研究Cohealyx-I已完成全部患者入组工作,而另一项重点研究Permeaderm-I在2025年12月时入组进度亦突破75%。这两项针对皮肤再生技术的临床试验,均计划于2026年晚些时候公布详细数据结果。
Avita Medical Ltd.宣布,其关键临床研究Cohealyx-I已完成全部患者入组工作,而另一项重点研究Permeaderm-I在2025年12月时入组进度亦突破75%。这两项针对皮肤再生技术的临床试验,均计划于2026年晚些时候公布详细数据结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.